Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 20 May 24 424B3 Prospectus supplement
- 14 May 24 424B3 Prospectus supplement
- 28 Mar 24 424B3 Prospectus supplement
- 2 Feb 24 424B4 Prospectus supplement with pricing info
- 2 Feb 24 EFFECT Notice of effectiveness
- 31 Jan 24 S-1/A IPO registration (amended)
-
30 Jan 24 S-1/A IPO registration (amended)
- 26 Dec 23 UPLOAD Letter from SEC
- 21 Dec 23 S-1 IPO registration
GRI similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the inclusion in this Amendment No. 1 to the Registration Statement of GRI Bio, Inc. (formerly Vallon Pharmaceuticals, Inc.) on Form S-1 to be filed on or about January 30, 2024 of our report dated February 23, 2023, on our audits of the Vallon Pharmaceutical, Inc. financial statements as of December 31, 2022 and 2021 and for each of the years then ended. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern. We also consent to the reference to our firm under the caption “Experts” in this Registration Statement.
s/ EisnerAmper LLP | ||
EISNERAMPER LLP | ||
Iselin, New Jersey | ||
January 30, 2024 |